Lineage Cell Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
AMEX
Jorey Chernett has reported beneficial ownership of 5.01% of Lineage Cell Therapeutics, Inc.'s common stock, totaling 11,445,003 shares.
AMEX
SCHEDULE 13G/A: BlackRock Discloses 1.0% Stake in Lineage Cell Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 1.0% beneficial ownership stake in Lineage Cell Therapeutics Inc., totaling 2,234,545 common shares.
AMEX
BlackRock, Inc. has filed a Schedule 13G, revealing a 5.0% beneficial ownership stake in Lineage Cell Therapeutics Inc., totaling 11,453,305 common shares.
AMEX
SCHEDULE 13G/A: BlackRock Amends Passive Stake in Lineage Cell Therapeutics, Reports 4.6% Beneficial Ownership
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.6% beneficial ownership stake in Lineage Cell Therapeutics Inc. as of December 31, 2024.